Assessing the correlation between second progression-free survival (PFS2) and overall survival (OS) in advanced prostate cancer patients using medical data vision (MDV) claims database in Japan

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Mo M, Wei Y, et al. Epidemiology and genomics of prostate cancer in Asian men. Nat Rev Urol. 2021;18(5):282–301.
   PubMed Web of Science ®Google Scholar
• Chang AJ, Autio KA, Roach M, et al. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014;11(6):308–323.
   PubMed Web of Science ®Google Scholar
• Grozescu T, Popa F. Prostate cancer between prognosis and adequate/propertherapy. J Med Life. 2017;10(1):5–12.
   PubMedGoogle Scholar
• Maggi M, Salciccia S, Del Giudice F, et al. A systematic review and meta-analysis of randomized controlled trials with novel hormonal therapies for non-metastatic castration-resistant prostate cancer: an update from mature overall survival data. Front Oncol. 2021;11(700258):700258.
   PubMed Web of Science ®Google Scholar
• Lokeshwar SD, Klaassen Z, Saad F. Treatment and trials in non-metastatic castration-resistant prostate cancer. Nat Rev Urol. 2021;18(7):433–442.
   PubMed Web of Science ®Google Scholar
• Komura K, Sweeney CJ, Inamoto T, et al. Current treatment strategies for advanced prostate cancer. Int J Urol. 2018;25(3):220–231.
   PubMed Web of Science ®Google Scholar
• Esther J, Dorff TB, Maughan BL. Recent developments in the treatment of non-metastatic castration resistant prostate cancer. Cancer Treat Res Commun. 2020;24:100181.
   PubMedGoogle Scholar
• Sciarra A, Maggi M, Salciccia S, et al. Tissue expression of androgen receptor splice variant 7 at radical prostatectomy predicts risk of progression in untreated nonmetastatic prostate cancer. Oncology. 2021;99(4):251–255.
   PubMed Web of Science ®Google Scholar
• FDA [Internet]. Clinical trial endpoints for the approval of cancer drugs and biologics guidance for industry; 2018 [cited 2021 Jan 11]. Available from: https://www.fda.gov/media/71195/download.
   Google Scholar
• Mbanya Z, Chadda S. Time to second objective disease progression (PFS2): an emerging clinical trial endpoint with regulatory and reimbursement implications. Blood. 2014;124(21):6005–6005.
   Web of Science ®Google Scholar
• EMA [Internet]. Guideline on the evaluation of anticancer medicinal products in man; 2017 [cited 21 Dec 11]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-anticancer-medicinal-products-man-revision-5_en.pdf.
   Google Scholar
• Kordecka A, Walkiewicz-Zarek E, Lapa J, et al. Selection of endpoints in clinical trials: trends in European marketing authorization practice in oncological indications. Value Health. 2019;22(8):884–890.
   PubMed Web of Science ®Google Scholar
• Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat Med. 2012;31(25):2973–2984.
   PubMed Web of Science ®Google Scholar
• Lux MP, Ciani O, Dunlop WCN, et al. The impasse on overall survival in oncology reimbursement decision-making: how can we resolve this? Cancer Manag Res. 2021;13:8457–8471.
   PubMed Web of Science ®Google Scholar
• Chowdhury S, Mainwaring P, Liangcai Z, et al. Systematic review and meta-analysis of correlation of progression-free survival-2 and overall survival in solid tumors. Front Oncol. 2020;10:1349.
   PubMed Web of Science ®Google Scholar
• Lorente D, Castro E, Lozano R, PROREPAIR-B Study Investigators, et al. Association between second progression-free survival (PFS2) and overall survival in metastatic castration-resistant prostate cancer. Eur Urol. 2020;77(6):763–766.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Chowdhury S, et al. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021;79(1):150–158.
   PubMed Web of Science ®Google Scholar
• Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13–24.
   PubMed Web of Science ®Google Scholar
• Saad F, Efstathiou E, Attard G, et al. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2021;22(11):1541–1559.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408–1418.
   PubMed Web of Science ®Google Scholar
• Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465–2474.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–360.
   PubMed Web of Science ®Google Scholar
• James ND, de Bono JS, Seaprs MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–351.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–148.
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433.
   PubMed Web of Science ®Google Scholar
• Leclezio L, Jansen A, Whittemore VH, et al. Pilot validation of the tuberous sclerosis-associated neuropsychiatric disorders (TAND) checklist. Pediatr Neurol. 2015;52(1):16–24.
   PubMed Web of Science ®Google Scholar
• Wu DBC, Manjula SI, Yu DY. POSA302: the association between progression-free survival and overall survival in oncology trials: a simulation exercise. Value Health. 2021;24(12):S2.
   Google Scholar
• Oronsky B, Carter CA, Reid TR, et al. Confirmatory trials in the evaluation of anticancer medicinal products in man–PFS2: a measure of therapeutic action-at-a-distance. Neoplasia. 2015;17(9):716–722.
   PubMed Web of Science ®Google Scholar
• Somarouthu B, Lee SI, Urban T, et al. Immune-related tumour response assessment criteria: a comprehensive review. Br J Radiol. 2018;91(1084):20170457.
   PubMed Web of Science ®Google Scholar